Aug 7, 2026 – 12.46pmResmed chief executive Mick Farrell says the introduction of weight loss pills in the United States is helping to boost sales of his sleeping devices because more patients are getting diagnosed with breathing disorders when they go to the doctor to get GLP-1 prescriptions.Investors in the ASX-listed sleep device manufacturer remain nervous about the rise of weight-loss drugs like Wegovy and Mounjaro because of their potential to reduce the number of people with sleep apnoea as they lose weight. But so far, the popularity of the drugs has had the opposite effect.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Fetching latest articles